Article
Use of whole-genome sequencing to distinguish relapse from reinfection in a completed tuberculosis clinical trial.
BMC medicine - 29 Mar 2017
Witney Adam A, Bateson Anna L E, Jindani Amina, Phillips Patrick P J, Coleman David, Stoker Neil G, Butcher Philip D, McHugh Timothy D
Abstract excerpt
BACKGROUND: RIFAQUIN was a tuberculosis chemotherapy trial in southern Africa including regimens with high-dose rifapentine with moxifloxacin. Here, the application of whole-genome sequencing (WGS) is evaluated within RIFAQUIN for identifying new infections in treated patients as either relapses or reinfections. WGS is further compared with mycobacterial interspersed repetitive units-variable number tandem...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
